

August 30, 2018

To,
Mr. Avishkar Naik
Vice President Surveillance
National Stock Exchange of India Ltd,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.
Ref: Scrip Name: GLENMARK

Dear Sir,

Sub:- Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015

This has reference to your email dated August 10, 2018 and our reply to the said email on the same date in relation to the news item titled "True North in talks to buy into Glenmark API biz for Rs 1500 cr" that appeared in the Economic Times on August 10, 2018, we would like to state that this news was incorrect.

We had informed the Exchange regarding Glenmark's collaboration with True North for orthopaedic business and transfer of Glenmark's API business to its wholly-owned subsidiary, subject to the approval of shareholders, immediately after these developments were approved by the Board of Directors in the meeting on August 10, 2018.

We have been proactive in informing the Exchange about the events of the Company and we will continue to do so.

Requesting you to kindly take the same on record.

Thanking You.

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.



Harish Kuber
Company Secretary & Compliance Officer